Tight regulation of coagulation proteases is required for normal haemostasis in the kidney. Coagulation is intimately associated with inflammation and the func tions of the haemostatic system extend beyond main ten ance of vascular integrity and prevention of excessive blood loss. This crosstalk is reflected phylogenetically by the haemocyte or amoebocyte, the sole circulating blood element of the horseshoe crab (Limulus polyphemus) 1 , which simultaneously fulfils the functions of platelets and phagocytic cells. Vertebrates do not have a single cell type that unifies the coagulation system and innate inflammatory regulators, but soluble coagulation pro teases regulate haemostasis as well as inflammation and tissue remodelling 2 . The close association of inflammation and tissue remodelling with renal disease has prompted research ers to address the functions of haemostatic regulators in this setting. The discovery of proteaseactivated recep tors (PARs), the pivotal cellular receptors for coagulation proteases, provided new impetus leading to novel patho genic concepts in various organ systems. Moreover, the increasing clinical utilization of anticoagulants targeting specific coagulation proteases and the advent of PAR antagonists warrant additional investigation to gain deeper insights into the mechanisms through which the coagulation system modulates renal health 3, 4 (TABLE 1) .
Such knowledge might enable nephrologists to exploit the beneficial effects of such interventions while simulta neously avoiding the detrimental aspects. In this Review we summarize current knowledge regarding the role of coagulation proteases in renal disease.
The coagulation system
The coagulation system is traditionally viewed as a cascade like system with two activation pathways: the tissue factor (TF; also known as extrinsic) pathway and the contact (also known as intrinsic) pathway 5 
(FIG. 1).
TF is a type 1 transmembrane receptor that shares substantial structural homology with type II cytokine receptors. Full length TF is a 263 amino acid, single chain poly peptide with a 219 amino acid extracellular Nterminus, a 23 amino acid transmembrane domain and a 21 amino acid intracellular Cterminus 6 . As TF is physiologically expressed by perivascular cells but not by resting endothelial cells, leucocytes or other cells in direct contact with blood (with the exception of placen tal trophoblasts and cancer cells), it comes into contact with blood only upon vascular injury or following its induction (for example by inflammatory cytokines) on endothelial cells or leucocytes.
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The emerging role of coagulation proteases in kidney disease Thati Madhusudhan 1 , Bryce A. Kerlin 2 and Berend Isermann 1 Abstract | A role of coagulation proteases in kidney disease beyond their function in normal haemostasis and thrombosis has long been suspected, and studies performed in the past 15 years have provided novel insights into the mechanisms involved. The expression of protease-activated receptors (PARs) in renal cells provides a molecular link between coagulation proteases and renal cell function and revitalizes research evaluating the role of haemostasis regulators in renal disease.
Renal cell-specific expression and activity of coagulation proteases, their regulators and their receptors are dynamically altered during disease processes. Furthermore, renal inflammation and tissue remodelling are not only associated, but are causally linked with altered coagulation activation and protease-dependent signalling. Intriguingly, coagulation proteases signal through more than one receptor or induce formation of receptor complexes in a cell-specific manner, emphasizing context specificity. Understanding these cell-specific signalosomes and their regulation in kidney disease is crucial to unravelling the pathophysiological relevance of coagulation regulators in renal disease. In addition, the clinical availability of small molecule targeted anticoagulants as well as the development of PAR antagonists increases the need for in-depth knowledge of the mechanisms through which coagulation proteases might regulate renal physiology.
TF is induced in diverse renal diseases and modu lates renal function through various mechanisms. It lacks intrinsic proteolytic activity, but can bind factor VII or factor VIIa in a Ca 2+ dependent manner, promoting factor VII activation or enhancing the catalytic activity of factor VIIa 7 . The TF/VIIa complex interacts with and activates factor IX and factor X. Activated factor X ena bles formation of the prothrombinase complex (com prised of factor Xa, factor Va, calcium and negatively charged phospholipids of activated cells such as platelets). The prothrombinase complex promotes the conversion of prothrombin to thrombin (also known as factor IIa). Although the initial quantity generated is small, throm bin initiates an amplification loop via factor XIa genera tion, activates the nonproteolytic cofactors V and VIII (resulting in an ~1,000fold acceleration in thrombin generation) and recruits activated platelets, thus ensur ing the localized production of haemostatic thrombin concentrations (FIG. 2) . Subsequently, thrombin acti vates fibrinogen and platelets (via PARs), generating fibrinplatelet aggregates known as blood clots.
The role of the contact pathway in coagulation has been redefined in the past decade 8 . A series of elegant studies have established a factor XIIdependent mech an ism in the pathophysiology of thromboocclusive dis eases, even though factor XII activation is dispensable for haemostasis 8 . These studies demonstrate that haemo stasis (prevention of excessive blood loss) and throm bosis (excess thrombus formation) are mechanistically separable, suggesting that pharmaceutical interventions that target pathological thrombosis without interfering with normal haemostasis are feasible 9 . The dependence of factor XII activation on negatively charged surfaces has been known for almost a century 10 , but the importance of this phenomenon was eluci dated only in the past decade, with the discovery that polyphosphates have the ability to enhance factor XII activation 8, 11, 12 . This effect and additional polyphosphate dependent effects on the coagulation system, such as promoting factor V activation and enhancing the anti fibrinolytic activity of thrombin activable fibrinolysis inhibitor (TAFI, also known as carboxypeptidase B2), depend on the polymer length, which varies depending on the source (for example, very long polymers pres ent in microorganisms and shorter polymers present in platelets) 11, 13 . Several physiological anticoagulant mechanisms pre vent excessive coagulation activation. Tissue factor path way inhibitor (TFPI) is a Kunitztype protease inhibitor that constrains the activity of the TF/factor VIIa and prothrombinase complexes, thus restricting initiation of coagulation. The serine protease inhibitor antithrombin (also known as antithrombin III) inhibits multiple coagu lation proteases, including its primary target thrombin and factors VIIa, IXa, Xa, XIa and XIIa. Antithrombin also inhibits other serine proteases, such as kallikrein, plasmin and trypsin as well as the complement lec tin pathway. The inhibitory activity of antithrombin is enhanced ~2,000-4,000 fold in the presence of heparin 14 .
A more specific and equally important anti coagu lant mechanism is initiated by endothelial thrombo modulin, which modulates the function of thrombin. When bound to thrombomodulin, thrombin loses its procoagulant function but efficiently activates pro tein C 15 . Activated protein C (aPC) in turn inactivates cofactors Va and VIIIa, thus efficiently dampening amplification of thrombin generation. In addition, the thrombomodulin-thrombin complex activates TAFI, which removes Cterminal lysine and arginine residues from peptides. In the case of fibrin these Cterminal resi dues are required for tissuetype plasminogen activator (tPA)mediated activation of plasminogen. All of these anticoagulant regulators have functions in renal diseases.
The formation of a fibrin-platelet aggregate is not the final step in haemostasis and is succeeded by the equally wellcontrolled process of fibrinolysis. This proteolytic process is not restricted to fibrin but might also target the extracellular matrix. Plasminmediated fibrinolysis and degradation of extracellular matrix is highly relevant in the context of fibrotic renal diseases. In addition, the proteases involved in fibrinolysis might either activate or disarm PARs and can directly modulate cellular func tion through urokinase plasminogen activator receptor (uPAR) 16, 17 . The roles of fibrinolysis and uPAR in renal disease have been reviewed previously [17] [18] [19] .
Protease activated receptors
Beyond its indispensable haemostatic functions, the coagulation system has nonhaemostatic functions, for example in inflammation and tissue remodel ling. The discovery of PARs provided insight into the non haemostatic functions of coagulation proteases. Although well accepted in basic research, knowledge of these nonhaemostatic functions has not yet been translated into clinical applications.
PARs are members of the class A family of rhodopsin like G proteincoupled receptors (GPCRs) and are pre dominantly organized within lipid rafts 20 . Four distinct PARs have been identified (PAR1, PAR2, PAR3 and PAR4). Unlike the metabotropic members of the class C family of GPCRs, which are obligate dimers, PARs can function as protomers as well as heterodimers. This abil ity enables PARs to activate diverse signalling pathways in tissue, context and temporally specific fashions. PARs transmit cellular responses initiated by a number of coag ulation regulators, for example factor IIa (PAR1, PAR3 and PAR4), aPC (PAR1 and PAR3), factor Xa (PAR2) or
Key points
• In addition to their pivotal and well-established functions in haemostasis, coagulation regulators and receptors mediate non-haemostatic functions in the kidney • Derangements of the coagulation system and altered coagulation-proteasedependent signalling in renal disease might alter disease progression • Coagulation proteases alter the function of a variety of renal cell types via distinct protease-activated receptors (PARs) and co-receptors • Activated protein C has nephroprotective effects that are at least partly independent of its anticoagulant function • The new drug classes of target-specific oral anticoagulants and PAR inhibitors might interfere with the functions of coagulation proteases in renal disease, with potential beneficial or adverse effects plasmin (PAR1 and PAR4), as well as non coagulation proteases, for example matrix metalloproteinase 1 (PAR1), tryptase or matriptase (PAR2), cathepsin G (PAR4) and cathepsin S (PAR2) 15, 16, [21] [22] [23] [24] [25] [26] [27] [28] (TABLE 2) .
The functions of individual PAR protomers and downstream signalling cascades have been extensively studied, but the mechanisms of heterodimerization and their pathophysiological relevance remain incompletely explored. PARs have a unique activation mechanism: following cell surface localization the protease cleaves the extracellular Nterminus, unmasking a cryptic Nterminal sequence, which acts as a tethered ligand inducing a conformational rearrangement and irreversi ble activation of heterotrimeric G proteins 4, 26 (FIG. 3) . This mechanism is in contrast to that of most GPCRs, which are reversibly activated.
The expression of PARs is highly heterogeneous and more than one PAR is expressed on many cell types. In addition, expression of PARs in some cell types is spe cies specific. For example, human platelets express PAR1 and PAR4 and human podocytes predominately express PAR2 and PAR3, whereas murine platelets express PAR3 and PAR4 29 and murine podocytes predominately express PAR1 and PAR3 30 . The diversity of protease dependent signalling is furthermore exempli fied by the TF/VIIa/Xa complex and the serine proteases thrombin and aPC. The TF/VIIa/Xa complex can activate PAR2, but the cytoplasmic domain of TF (which can be phos phorylated but is dispensable for coagulation activation) indepen dently regulates cellular functions such as adhe sion or migration 31 . Thrombin directly interacts with PAR1, PAR3 and PAR4, whereas aPC interacts with PAR1 and PAR3. Despite activation of PAR1 and PAR3 by both thrombin and aPC, these proteases convey opposing cellular effects 20 . Biased (that is, functionally selective) and cellspecific PARmediated signalling is thought to result from distinct cleavage sites, which result in distinct neoNtermini, and cellspecific supramolecular recep tor complexes (that is, PAR signalosomes) 15, [23] [24] [25] . PARs can form homodimers or hetero dimers either consti tutively or upon activation, depending on the cell type, extracellular protease, specific PAR that is activated and the presence of coreceptors. In addition to PAR-PAR interactions, PARs can interact with other receptors (for example sphingosine 1phosphate receptor 1 [S1P1], epi dermal growth factor receptor [EGFR] and P2Y purino ceptor 12), emphasizing the involvement of cellspecific signalosomes [23] [24] [25] [26] (FIG. 3) .
Coagulation regulators and receptors
Coagulation regulators and receptors for coagula tion protease signalling are widely expressed in renal cell types (FIG. 4) . For example, thrombomodulin and endothelial protein C receptor (EPCR) are expressed on endothelial cells. Expression of thrombomodulin and EPCR is reduced in acute inflammatory states (for exam ple sepsis) or chronic diseases (for example dia betes mellitus) [32] [33] [34] . In a model of endotoxaemia, genetically modified mice with reduced EPCR expression (10% of wildtype levels) displayed enhanced albuminuria and renal haemorrhage, demonstrating a crucial role of EPCR in the regulation of vascular permeability in the kidney 35 . EPCR was likewise required for vascular protection in lung and brain, but to a lesser extent in other organs -an observation that is consistent with the concept of organspecific regulation of coagulation 35, 36 . An organspecific function has likewise been identi fied for the cytoplasmic domain of TF 37 . Mice that lack this domain express tumour necrosis factor (TNF) on their glomeruli from the age of 6 weeks and sponta neously develop albuminuria, podocyte effacement and loss 38 . They are sensitive to glomerular injury, but resistant to lipopolysaccharideinduced systemic inflam mation or arthritis [38] [39] [40] . The spontaneous pheno types of these mice exemplify the nonhaemostatic function of the coagulation system, as the cytoplasmic domain is not required for the procoagulant function of TF, but is involved in TF signalling. The renal pathology is exa cer bated in a glomerulonephritis model independent of leucocyte TF expression, suggesting a pathogenic func tion of renal TF expression 38, 41 . Although the pathophysi ological relevance of TF and the cytoplasmic domain has been shown in murine models, the expression pattern of TF in renal cell types remains to be characterized in mice [42] [43] [44] . Conversely, in humans and rabbits, glomeru lar TF expression has been demonstrated in podocytes, parietal epithelial cells and possibly also in mesangial cells [45] [46] [47] [48] . Notably, increased TF expression has been detected in acute and chronic kidney diseases (CKDs) in humans and rodents [49] [50] [51] [52] [53] . As TFPI is expressed in interstitial blood vessels, but not in glomeruli, glom erular TF expression is not opposed by concomitant TFPI expression 54 .
Tissue factor pathway (haemostasis)

Contact activation pathway (thrombosis)
Negatively charged surfaces
Common pathway (thrombin generation)
Feedback amplification Intriguingly protein C and protein C inhibitor (PCI), which were initially thought to be specific to the liver, are also expressed in renal cells 55 . Moreover, renal protein C expression is reduced in mice with systemic inflamma tion or diabetes 55 . PCI colocalizes with urokinase in proximal tubular cells (PTCs) and urokinase-PCI com plexes are readily detectable in urine 56 . Proinflammatory stimuli induce glomerular factor V expression, whereas ischaemia-reperfusion injury (IRI) induces tubular fibrinogen expression 53, [57] [58] [59] . Although endogenous expression of coagulation regulators such as TFPI, protein C, PCI, and factor V within renal cell types has been demonstrated, their pathophysiological relevance in regulating local coagulation and protease signal ling in kidney disease remains unknown and warrants additional investigation. Direct effects of coagulation proteases such as fac tor IIa or factor Xa on glomerular cells have long been known, implying receptordependent modulation of intracellular signalling pathways 53, 60 . A physiologi cal function of PARs was first demonstrated in 1991 (REF. 61); renal PAR1 activation conveys vasoconstriction and reduces glomerular filtration rate (GFR), whereas PAR2 activation causes vasodilation, partially reverses the vasoconstriction induced by PAR1 agonists or angi otensin II, and increases GFR 62 . Renal endothelial cells express PAR1, PAR2 and EPCR, whereas podocytes express PAR3, but lack EPCR, demonstrating the pres ence of distinct cellspecific receptor complexes 30 (FIG. 3) .
Intriguingly, podocytespecific expression of PAR1, PAR2 and PAR4 varies across species, whereas PAR3 expression is conserved across humans, mice and rats 30 . In human podocytes PAR3 dimerizes with PAR2 follow ing aPCmediated PAR3 activation, whereas in murine podocytes the cytoprotective effect of aPC depends on PAR3/PAR1 heterodimerization 30 . Murine mesan gial cells express PAR1 and PAR2 30, 63 and murine and human tubular cells express PAR1, PAR2 and EPCR; reports regarding the expression of PAR3 and PAR4 are conflicting, possibly reflecting different cell sources 34, 64, 65 . Integrins (for example αMβ2, β1 and β3) and other receptors such as apolipoprotein E receptor 2, platelet glycoprotein Ib α chain and S1P1 23 also interact with coagulation proteases, but little if anything is known about these interactions in the kidney.
Considering the wide expression of coagulation regu lators, their receptors and potential coreceptors by renal cells, autocrine and paracrine effects of coagulation proteases on renal function seem likely. This concept is supported by the experimental data discussed below. Endothelial dysfunction resulting in altered coagulation activation might, therefore, not only promote thrombus formation, but also impact other renal cell types, such as podocytes and tubular cells [66] [67] [68] .
Role of the glycocalyx
The glycocalyx regulates both capillary permeability and activation of coagulation 69, 70 . Although glycocalyx function remains incompletely characterized (reflect ing largely unmet analytical challenges), important insights have been gained for the endothelial glycocalyx, including that of glomerular endothelial cells 70 . The glycocalyx consists of covalently linked struc tures such as membranebound glycoproteins (for example, syndecan1 and thrombomodulin) and attached negatively charged glycosaminoglycans 71 . The membrane bound, multifunctional, anticoagulant pro tein thrombomodulin contains a chondroitin sulphate side chain, to which glycosaminoglycans are attached 71 . This loosely attached coat consists of secreted proteo glycans, including perlecan and hyaluronan. The glyco calyx has important roles in the transduction of shear stress, regulation of leucocyte-endothelial cell inter actions, selective permeability, growthfactor binding, and complement and coagulation regulation 71, 72 . Some of the endothelium and plasmaderived soluble molecules bound to the glycocalyx are important regulators of the glomerular filtration barrier and/or the coagulation sys tem (for example vascular endothelial growth factor A [VEGFA], protein C and antithrombin) [71] [72] [73] . Coagulation regulators that bind to the glycocalyx include thrombin, antithrombin, heparin cofactor 2 and TFPI. Heparan sulphates provide a scaffold for the inter action of antithrombin with procoagulant enzymes (such as thrombin, factor Xa and factor IXa), thus enhancing the anticoagulant effect several thousandfold. TFPI is thought to bind to the glycocalyx via heparan sulphates, but other proteins could also be involved 74 . Uptake and degradation of TFPI-factor Xa complexes also depends on heparan sulphates in the glycocalyx 75 . Heparin cofactor 2 is a thrombinspecific protease inhibitor, Upon vessel wall injury and/or activation of endothelial cells, tissue factor (TF) is exposed to blood and binds to FVII or FVIIa, promoting FVII activation or enhancing its catalytic activity. The TF-FVIIa (extrinsic tenase) complex activates small amounts of FIX and FX. FXa associates with FVa to form the prothrombinase complex, which cleaves FII to generate a small amount of thrombin. This initiation phase is followed by the amplification phase, in which thrombin activates cell-surface (predominately platelet) bound FV and FVIII and platelet-bound FXI. FIXa binds to FVIIIa on negatively charged surfaces (predominately platelet-derived phospholipids), activating FX (intrinsic tenase) and initiating a burst of thrombin generation-the propagation phase. Thrombin has pleotropic functions including feedback inhibition, fibrin formation, platelet activation and signalling through protease activated receptors. a, activated; F, factor.
which is activated by dermatan sulphate in the glyco calyx 71 . Likewise PCI inhibition of aPC requires binding to heparan sulphate 71 . All of these anticoagulant mol ecules within the glycocalyx contribute to the thrombo resistant nature of healthy endothelium. Quantitative and qualitative alterations of the glycocalyx, for example following toxic stimuli such as IRI or hyperglycaemia, modulate the bioavailability of these proteins 69, 76 . Loss of endothelial glycocalyx during acute hyperglycaemia coincides with endothelial dysfunction and coagulation activation in vivo 69 . Importantly, damage to the endothe lial glyco calyx has been demonstrated in patients with type 1 diabetes mellitus, the severity of which is increased in the presence of microalbuminuria 77 . These studies highlight the crucial pathophysiological rele vance of the endothelial glycocalyx. Further investiga tion is warranted to gain insight into the mechanistic relevance of glycocalyx components in the regulation of coagulation activation and glomerular permeability.
Modulation of haemostasis in renal disease
Thrombotic disease is a significant morbidity of renal diseases, especially in the settings of nephrotic syndrome and haemodialysis 78, 79 . The likelihood of thrombosis is also heightened in other kidney diseases, includ ing diabetic nephropathy, hypertensive nephropathy, glomerulo nephritis, interstitial nephritis and polycystic kidney disease 78 . In general the mechanisms underlying this increased risk remain illdefined [80] [81] [82] [83] [84] [85] [86] . In CKD, hypercoagulability is associated with mark ers of endothelial dysfunction (for example, increased levels of soluble thrombomodulin and changes in flowmediated dilatation) and inflammation (such as IL6) 87, 88 . Factor VIII and von Willebrand factor have been reported to contribute to venous thrombo embolism in patients with CKD, but both of these coagulation regulators are acute phase reactant pro teins, hence this observation might simply reflect an association of endothelial dysfunction (and secondary hypercoagula bil ity) with inflammation 84 . In patients with advanced CKD, plasma levels of soluble thrombo modulin are elevated, reflecting endothelial dysfunc tion, whereas levels of aPC are reduced, providing a potential link between CKD, endothelial dysfunction and hyper coagulability 87, [89] [90] [91] . These clinical observa tions provided the rationale for mechanistic studies of the endothelial thrombomodulin-protein C system in renal disease. Following kidney transplantation, markers of hyper coagulability and endothelial dys function (such as soluble thrombo modu lin and EPCR) normalize, suggesting that impaired renal function is causally related to hypercoagulability, potentially via endothelial dysfunction [92] [93] [94] . In addition to hypercoagulability, fibrin clots in patients with endstage renal disease (ESRD) are mark edly altered and characterized by a reduced porous structure, resistance to fibrinolysis and increased overall fibre thickness 95, 96 . These characteristics are associated with increased mortality and with a proinflammatory state, but not with azotaemia 95, 96 . The increased fre quencies of cardiovascular disease and cardiovascular death in patients with CKD have been postulated to be partly accounted for by coagulation activation and altered blood clot structure, but causality has not yet been established.
Effect of anticoagulation on renal function
In acute renal diseases, such as newlydiagnosed nephrotic syndrome, hypercoagulability is an impor tant comorbidity [97] [98] [99] , but prophylactic anticoagulation remains controversial 100, 101 . A similar situation exists for chronic renal diseases. In the context of diabetic nephropathy, researchers have evaluated whether hepa rins or other glycosaminoglycans improve renal func tion 102, 103 . In general these studies did not address the role of altered coagulation protease activity or signalling, but rather evaluated whether glycosaminoglycans can recon stitute negative charges within the glomerular filtration barrier -a concept that remains unproven 104 . Direct effects of anticoagulants on kidney homeostasis and renal disease progression remain undefined in acute and chronic renal diseases, but given the wide use of these therapies, such effects might have important clinical implications. The first study to evaluate the effect of the novel direct coagulation protease inhibitor rivaroxaban on renal function is now underway in patients with CKD and atrial fibrillation 105 . Both pharmacological anticoagulation and natu rally occurring anticoagulants have been demonstrated to positively affect nephron health [106] [107] [108] [109] [110] [111] [112] [113] [114] [115] . By contrast, supratherapeutic anticoagulation has been associated with accelerated loss of GFR [116] [117] [118] . These effects might potentially result in a vicious cycle, as many anti coagulants are dependent on renal clearance and might accumulate with worsening renal function. Although glomerular haemorrhage and tubular obstruction, par ticularly in patients with preexisting CKD, has been proposed to be causative, gross haematuria has only rarely been observed in these patients 118 . Other mech anisms of anticoagulantmediated glomerular injury should, therefore, be considered.
Interestingly, in rats PAR1 inhibition and the direct thrombin inhibitor dabigatran have similar detrimental effects on renal function to supratherapeutic anticoagu lation with warfarin 116, 119 . These findings demonstrate that these adverse effects are not specific to warfarin and -as rat platelets do not express PAR1 -might be dependent on PAR1 signalling in renal cells 116, 119 . In this context the protective effect of low but sustained thrombin activation observed in diabetic nephropathy, and the cytoprotective effect of low thrombin concentra tions in vitro on endothelial cells, podocytes and tubular cells are noteworthy, as they support the hypothesis that a low level of coagulation activation might be nephro protective. 65, 120 Such protective effects might be lost following supratherapeutic anticoagulation or direct thrombin inhibition.
The effects of coagulation protease inhibitors have been investigated in several preclinical studies 121, 122 . Notably, in a mouse model of sickle cell disease, the factor Xa inhibitor rivaroxaban had a greater anti inflammatory effect (characterized by a reduction in plasma levels of IL6) than the thrombin inhibitor dabigatran, despite a less potent anticoagulant dose, indicating specific differences between these inhib itors in relation to blood clotting and cytoprotective effects 123 . Mechanistically, direct suppression of the thrombin induced negativefeedback system by inhib iting thrombomodulin-thrombinmediated protein C activation might underlie these differential effects of factor Xa versus thrombin inhibition 124, 125 . In addition to their essential role in blood clotting, both factor Xa and thrombin can elicit multiple cellular effects via PARs and their coreceptors. Thrombin activates PAR1, whereas factor Xa can also signal via PAR2, directly or together with the TF-factor VIIa complex 122, 123, 126 . Consistent with these observations, inhibition of fac tor Xa but not of thrombin suppressed expression of the proinflammatory cytokine IL6, emphasizing the bene ficial effects of proteasespecific inhibition in a mouse model of sickle cell disease 123 . Determining whether direct anticoagulants differ in regard to their efficacy and safety in the context of renal function and disease will be of great clinical interest. Furthermore, elucidat ing the molecular mechanisms of coagulation protease signalling in renal cells might lead to new therapies that target the involved receptors and pathways without increasing the risk of glomerular haemorrhage.
Coagulation proteases in renal disease
Acute glomerular disease
The implications of glomerular coagulation activity and signalling have been thoroughly studied in the setting of rapidly progressive glomerulonephritis (RPGN). A key feature of RPGN is the formation of a fibrin matrix in the Bowman capsule, which forms the basis for the patho gnomonic crescentshaped scar seen in kidney biopsy samples. Fibrinogendeficient mice are partially resist ant to antibodymediated (antiglomerular basement membrane) RPGN 127 . Despite beneficial effects in preclinical and early nonrandomized clinical observational studies, therapies aimed at reducing fibrin deposition have not been suc cessfully translated into the clinic 128, 129 . This failure might reflect the inherent haemorrhage risk of such therapies and the now wellestablished multifaceted functions of the coagulation system, which are partially independ ent of fibrin formation. Once formed, fibrin is regulated 
non-PAR receptors
Figure 3 | Potential mechanisms of PAR activation by thrombin and aPC. An example scheme of protease activated receptors (PARs) and the N-terminal sequences of human PAR1 and PAR3 depicting distinct cleavage sites for thrombin and activated protein C (aPC; arrows). The qualitatively distinct signalling mechanisms of thrombin and aPC can be attributed to the distinct proteolytic activation mechanisms of the G protein-coupled receptor (GPCR) N-terminus, resulting in protease-specific tethered ligands (shown in red for thrombin and blue for aPC) or induction of distinct protease-specific signalling complexes. PAR3 is not considered to be signalling competent and the function of the tethered ligands remains incompletely resolved. Activation of PARs might elicit protease-specific classical GPCR signalling by activation of individual PAR receptors (that is protomers) or ligand-specific PAR-PAR heterodimers. In addition, coagulation-protease-dependent signalling might engage non-PAR receptors, enabling biased signalling and thus leading to signalling diversity. Other proteases can cleave PARs at different sites, for example matrix metalloproteinase-1 cleaves PAR1 at Asp39 and neutrophil elastase cleaves PAR-1 at Leu45.
by the plasmin system (FIG. 5) . Mice with plasminogen or tPA deficiency are prone to exacer bated RPGN 129 . Interestingly, deficiency of urokinase plasminogen acti vator (uPA), or its receptor uPAR, reduced glomerular macrophage infiltration, but did not significantly alter the RPGN disease course 130 . The proinflammatory cytokine IL1β, which is released from infiltrating mononuclear cells in experimental RPGN, upregulates glomerular expression of tPA, but not uPA, and downregulates the tPA inhibitor plasminogen activator inhibitor1 (PAI1) in cultured mesangial cells [131] [132] [133] . Mice deficient in PAI1 are partially protected from experimental RPGN, whereas those that transgenically overexpress PAI1 have exac erbated disease, suggesting that compensatory changes in tPA and PAI1 expression are inadequate to control experi mental RPGN 134 . A function of the fibrinolytic system nephroprotection is further supported by a study in which pharmacological inhib ition of TAFI conveyed protective effects in mice with acute glomerulonephritis by promoting fibrinolysis 135 . During RPGN, coagulation activation and subse quent fibrin deposition seem to be dependent on TF expressed by infiltrating mononuclear cells 47, 136 . An associ ation of increased TF expression with glomerular fibrin deposition and renal failure has been shown in human RPGN and in rabbit models 47 . Administration of antiTF antibody in rabbits ameliorated these changes without affecting macrophage infiltration, indicating that TF is the major in vivo initiator of fibrin deposition and renal failure in RPGN 47 . Specific thrombin inhibi tion using the naturally occurring anticoagulant hirudin ameliorated crescent formation, glomerular Tcell and macrophage infiltration, and serum creatinine eleva tion, emphasizing the pathophysiological relevance of thrombin in this disease model 137 . Similarly, factor Xa inhibition ameliorated the disease phenotype in rats with experimental mesangioproliferative glomerulo nephritis in a manner that was suggested to be depend ent on mesangial cell PAR2 signalling 53, 106, 138 . Indeed, signalling by procoagulant proteases that are activated downstream of TF might contribute to RPGN independ ent of fibrin formation and dissolution. Thus, PAR1 or PAR2 knockout diminished progression of experimen tal glomerulonephritis in mice, demonstrating that PAR signalling drives this immunecellmediated glomerular disease 137, 139 . Although these studies clearly establish a pathogenic role of coagulation proteases and PARs in acute glomerular diseases, the dynamics of receptor activation and interaction remain unknown.
In a mouse model of thrombotic microangiopathy (TMA) induced by various murine monoclonal and human antiphospholipid antibodies, glomerular TF expression was markedly enhanced and TF seemed to be a common mediator of glomerular injury 43 . Following exposure to these antibodies, which had anti phospholipid activity, both TF expression and com plement activation (that is, glomerular C3 deposition) were increased; C5a receptor (C5aR) deficiency partially protected against these effects. Importantly, genetic or pharmacological (using pravastatin) reduction of TF expression prevented renal injury irrespective of whether the antibodyinduced glomerular injury, and increased TF expression occurred via a complementdependent or complementindependent pathway 43 . These studies established a causal relationship of TF in regulation of acute glomerular injury, which is partially potentiated by complement activation.
Induction of TF expression following C5aR sig nalling has also been shown in human and murine neutro phils 140, 141 and the functional interaction of TF and complement might reflect the wellestablished communication between these systems 142 . In addition to inducing TF expression, the complement C5b7 com plex might activate TF by oxidizing its disulphide bond (via proteindisulphideisomerasedependent thiol disulphide exchange), resulting in optimal TF folding and oxidation and thus contributing to TF activation 7, 143 . Intriguingly, thrombomodulin, the functional opponent of TF in coagulation activation, dampens complement activation 144 and thrombomo dulin polymorphisms are associated with atypical haemolytic uraemic syn drome (HUS) 145 . Thrombomodulin dampens comple ment activation via activation of TAFI (via removal of carboxyterminal arginines from C3a and C5a) and through a poorly defined mechanism involving the lectinlike domain 144, 146 . Deficiency of the lectinlike domain of thrombomodulin worsened Shigatoxin induced experimental HUS in mice; these mice showed enhanced renal impairment and increased glomerular complement and fibrin deposition compared with wildtype controls 147 . Whether thrombomodulin functionally interacts with TF via complement regula tion in the context of glomerular disease has not yet been addressed.
The renin-angiotensin-aldosterone system (RAAS) is integrally involved in the progression of many kid ney diseases 148 . Signalling through angiotensin II type 1 and angiotensin IV receptors upregulates expression of PAI1 148 . In addition, aldosterone stimulates renal PAI1 expression and PAI1deficient animals are protected from aldosteroneinduced glomerulosclero sis 149, 150 . These effects are thought to occur via amelio ration of PAI1mediated suppression of plasmin and matrixmetalloproteinasemediated degradation of extracellular matrix proteins that are involved in renal fibrosis 148 . Interestingly, plasmin can either disarm or activate PAR1 by proteolytic cleavage and might also sig nal via PAR4 (TABLE 2) . The implications of PAI1 altera tions on plasminmediated cell signalling in the kidney remain unexplored in the contexts of RAASmediated renal fibrosis and glomerulonephritis 151, 152 . Nonspecific coagulation inhibition with hepa rin or antithrombin reduces proteinuria in the puro mycin aminonucleoside and adriamycin experimental models of nephrotic syndrome [153] [154] [155] [156] . Unfortunately, owing to the nonspecific nature of these inhibitors it remains unclear which protease(s) are involved in per sistent proteinuria. Circulating protease activity from patients with nephrotic syndrome has, however, been demonstrated to injure cultured podocytes in what seems to be a PAR1dependent manner, implicat ing PAR1 cleaving proteases as promising targets for further investigation 151, 157 . Thrombin signalling via PAR1 might involve transactivation of PAR2. Increased fibrin deposition contributes to the formation of glomerular crescents, which is inhibited by plasmin-mediated fibrinolysis. Inhibition of plasmin by plasminogen activator inhibitor-1 (PAI-1), which might be induced via the renin-angiotensin-aldosterone system (RAAS) or activated thrombin activatable fibrinolysis inhibitor (TAFIa), abolishes this effect. b | In acute tubular injury inflammation, for example in the context of ischaemia-reperfusion injury (IRI), induces TF expression on inflammatory cells or potentially on tubular epithelial cells themselves, triggering coagulation activation within the tubular compartment. Thrombin signalling via PAR1 leads to transforming growth factor β (TGF-β)-dependent tissue remodelling and tubular injury, whereas activated protein C (aPC) signalling via PAR1-endothelial protein C receptor (EPCR) inhibits TGF-β-dependent tubular fibrosis and preserves expression of YB-1 by restricting its ubiquitin-dependent degradation, thereby preventing tubular injury. Excess fibrin formation induces tubular injury, whereas moderate fibrin generation triggers fibrinolysis, leading to extracellular matrix (ECM) degradation and generation of the fibrin-derived peptide Bβ15-42, which blocks the interaction of fibrin with intercellular adhesion molecule 1 (ICAM-1). Moderate fibrin deposition, therefore, contributes to renal recovery. Green inhibitory arrows indicate that inhibition promotes repair; red inhibitory arrow indicates that inhibition promotes injury. a, activated; AT, antithrombin; F, factor; TM, thrombomodulin.
Acute tubular disease
The effects of coagulation proteases on renal tubular health have been addressed in several studies. In the con text of IRI, limited fibrin formation is required for tissue repair; complete fibrinogen deficiency severely impairs renal function, whereas reduced fibrinogen expres sion protects against ischaemic injury in heterozygous fibrinogen knockout mice (FIG. 4) 57,158
. The fibrin derived peptide Bβ1542 protects kidneys from IRI, potentially by competitively blocking binding of fibrin to integrins, ICAM1 or VEcadherin, thus altering cellular signalling and reducing apoptosis 57, 159, 160 . A protective effect of the Bβ1542 peptide is apparent even if applied postinjury and might involve preservation of endothelial and vascu lar integrity 57, 161 . The observation that urinary fibrinogen might be a marker of acute kidney injury (AKI) is also of potential clinical relevance 162 . The coagulation system clearly also has functions that are independent of fibrin formation in AKI. Thus, defi ciencies in TF or PAR1 are protective in renal IRI and impaired thrombomodulindependent protein C acti vation worsens disease outcomes 34, 52 . In renal IRI, aPC -independent of its anticoagulant function -sustains intracellular levels of the coldshock protein YB1 by restricting its ubiquitination and degradation through PAR1 -EPCR signalling in tubular cells 34 . These stud ies have identified a new mechanism through which coagulation proteases modulate cellular function in AKI.
Additional roles for coagulation signalling in tubular epithelial cells might influence renal outcomes. A prom inent example is the discovery that plasmin activates sodium and calcium channels of PTCs during nephrotic range proteinuria 163, 164 . These proteasemediated altera tions in ion channel function might at least partly explain oedema formation in nephrotic syndrome. Furthermore, thrombin stimulates proliferation and proinflammatory responses in cultured human PTCs 64, 165 . These responses can be recapitulated with PAR2 activating peptides but not with other PAR agonists; this finding is interesting because thrombin is not known to cleave PAR2 16, 151 . When cleaved, however, the PAR1tethered ligand might transactivate PAR2 that is heterodimerized to PAR1, potentially explaining these data 27 . These responses to thrombin seem to be TGFβdependent. PAR1 cleav age by aPC bound to EPCR seems to counteract the effect of thrombin by downregulating TGFβmediated production of profibrotic extracellular matrix proteins by PTCs 64, 65 . The fibrinolytic system might also be involved in tubular injury. Mice that overexpress PAI1 develop sig nificantly aggravated renal fibrosis in response to ureteral obstruction, compared with wildtype mice 166 . These effects might be mediated through a downstream reduc tion in extracellular matrix degradation, as proposed to occur for the RAAS in the glomerulus 148 . The effects of PAI1 modulation on downstream plasmin -PAR1 signalling have not yet been investigated.
Together the available data suggest that coagulation derangements and egress of coagulation proteins into the renal interstitium and/or urinary space might influence disease progression. The implications of coagulation protease signalling in acute kidney diseases likely extend beyond those described in this Review. For example, coagulation is known to be activated in complement (HUS) and noncomplement (TTP) mediated thrombotic microangiopathy (TMA) 43 . Notably thrombo modulin has been shown to regulate complement in atypical HUS 145 . Renal injury in the setting of TMA is thought to be medi ated, at least in part, by ischaemic effects secondary to small artery thrombosis. However, the implications of downstream cellular injury mediated by activated coag ulation protease signalling remains unexplored in these settings. Anticoagulation with heparin might modulate complement system activity, reflecting the close inter action of the complement and coagulation systems and suggesting that it might be possible to pharmaceutically target and utilize these systems in AKI 167 .
Chronic kidney disease CKD (defined as estimated GFR <60 ml/min/1.73 m 2 ) is an increasing medical problem, which afflicts ~26 mil lion people in the USA alone. As outlined above, hypercoagulability in CKD is well documented, but the underlying mechanisms remain poorly defined. Hypercoagulability might be linked to altered clearance or inactivation of coagulation regulators, uraemic toxins, electrolyte and acid-base abnormalities and/or endothe lial dysfunction. The loss of renal thrombomodulin expression and other procoagulant and proinflamma tory regulators during ageing might depend on NFκB signalling, consistent with a role of this transcription factor in the regulation of coagulation regulators 32, 168 . Fibrinolysis regulators are also activated in CKD 169 and both impaired fibrinolytic activity and hyperfibrinolysis have been described 88, 170, 171 . Plasma levels of PAI1 are increased in patients with CKD, including those with diabetic nephropathy 18 . To date, most existing studies of the role of haemostatic regulators in CKD have focused on diabetic nephropathy -a leading cause of ESRD.
Diabetic nephropathy
Fibrin deposition is increased in diabetic glomeruli and is associated with glomerular extracellular matrix accumulation (FIG. 6) 
172,173
. Thrombininduced mesangial TGFβ expression and an increased peripheral blood PAI1 to tPA ratio in diabetic patients might contrib ute to these changes 174, 175 . The function of the endothe lial thrombomodulin-protein C system is impaired in patients with diabetic nephropathy, as reflected by increased plasma levels of soluble thrombomodulin and reduced levels of aPC 176, 177 . Animal studies have been instrumental in decipher ing the role of coagulation proteases in diabetic nephro pathy. TF expression is increased in diabetic mice (db/db and streptozotocin models), along with increased expres sion of PAR2 (db/db mice show a transient increase at 20 weeks) and factor V 51, 58 . Increased TF expression has been observed in tubular cells and glomerular parietal cells 51 , whereas glomerular thrombomodulin expression is reduced in diabetic mice 33 . Studies involving genetic modification of the thrombomodulin-protein C system established that loss of thrombomodulindependent protein C activation aggravates diabetic nephropathy, whereas compensation for impaired protein C activation protects against the disease 33 . Exogenous application of aPC likewise ameliorated diabetic nephropathy in mice, demonstrating that the underlying mechanism can, in principle, be pharmacologically targeted 178, 179 . As the nephroprotective effect of aPC is independent of its anticoagulant properties, the possibility exists that the underlying mechanism could be utilized with out interfering with the haemostatic system 30, 179 . aPC engages distinct receptor complexes (PAR1-EPCR on endothelial cells and PAR3 in podocytes) to ameliorate glucose toxicity. In podocytes aPC signalling via PAR3 trans activates PAR2 in humans or PAR1 in mice 30 . Given the speciesspecific expression of PARs in podocytes, results obtained in mice, for example when evaluating new thera peutic strategies or the risk of adverse effects, cannot generally be extrapolated to humans.
Association of the PAR3/PAR2 dimer with caveolin 1 is also required for the cytoprotective effect of aPC in vitro 30 . aPC reduces caveolin1 Tyr14 phosphory lation in a timedependent manner and this aPC mediated dephosphorylation enables the dissociation of caveolin1 from PAR2 and PAR3, effectively inhibit ing podocyte apoptosis 30 . The mechanistic importance of PAR-caveolin interactions has likewise been estab lished in endothelial cells, in which compartmentaliza tion of PAR1 into caveolar microdomains determines the barrier protective versus barrier disruptive effects of aPC and thrombin, respectively 20 . Whether these observations made in HUVEC-derived EA.hy926 cells can be extrapolated to glomerular endothelial cells remains unknown. Based on the available data, however, it can be concluded that proteases convey their effects in renal cells through cellspecific PAR signalo somes 180 . The characterization of these signalosomes and the Independent of aPC generation, thrombomodulin inhibits complement activation via its lectin-like domain and ameliorates diabetic nephropathy. b | Chronic inflammation triggers fibrin generation in the tubulointerstitial compartment, contributing to tubular injury. Plasmin-mediated degradation of fibrin and ECM inhibits this process, but this tissue-protective mechanism is inhibited by thrombin-mediated activation of thrombin activable fibrinolysis inhibitor (TAFI). Green inhibitory arrow indicates that inhibition promotes repair; red inhibitory arrow indicates that inhibition promotes injury. a, activated; EC, endothelial cells; F, factor; P, podocytes; PAI-1 plasminogen activator inhibitor-1; ROS, reactive oxygen species; TGF-β, transforming growth factor β; tPA, tissue-type plasminogen activator. 
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Thrombin Nature Reviews | Nephrology downstream signalling events might facilitate the identi fication of small molecules that target these proteasein duced cytoprotective mechanisms. In diabetic nephropathy, aPC epigenetically supresses the redox enzyme p66
Shc and thereby limits sustained generation of mitochondrial reactive oxygen species 179 . These effects are dependent on thrombomodulin mediated protein C activation on endothelial cells and aPC/PAR3 signalling in podocytes, establishing an endothelialtopodocyte crosstalk mechanism 179 . This coagulationproteasedependent crosstalk complements the VEGF and angiopoietin crosstalk at the glomerular filtration barrier, which is controlled by podocytes 181 . In the diabetic milieu this coagulationproteasedependent crosstalk is disturbed, impairing the glomerular filtra tion barrier and podocyte function, thus contributing to diabetic glomerulopathy.
Consistent with the in vitro concentrationdependent effects of thrombin in tubular cells and podocytes, mice with low but sustained thrombin generation owing to the factor V Leiden (FVL) mutation are partially pro tected from diabetic nephropathy 120 . This effect is lost following anticoagulation with the direct and irreversi ble thrombin inhibitor hirudin, indicating a protective role of thrombin generation at low levels 120 . Whether low thrombin concentrations directly convey cytoprotective signalling, as suggested by in vitro studies, or whether indirect effects such as protein C activation convey cytoprotection, remains unknown 120, 182 . Importantly, the FVL mutation is associated with reduced albuminuria in diabetic and prediabetic individuals, demonstrating the relevance of this phenomenon in patients 120, 183 . The apparent nephroprotective effect of low throm bin concentrations might relate to controversial data obtained from the use of anticoagulants in animal models of diabetic nephropathy. Initially, heparins were thought to replenish negatively charged glycosamino glycans in the glomerular filtration barrier, thus restoring its function 184, 185 . This possibility cannot be completely refuted, but other mechanisms for the nephroprotective effect should be considered. Efficient thrombin inhib ition is expected to impair both protein C activation and direct cytoprotective signalling. Furthermore, thrombin and factor Xa activate different receptors; hence anti coagulation with direct thrombin or factor Xa inhibitors might have distinct consequences. Thus, fondaparinux, a selective factor Xa inhibitor, conveys partially protec tive effects in db/db mice (that is, it has a minor effect on albuminuria and slightly reduces glomerular size), con trasting with the disadvantageous effects of hirudin 58, 120 . Considering the increasing availability and use of small molecule anticoagulants, and the recent introduction of the first PARantagonist for clinical use, studies deci phering the effects of these new drugs on glomerular function and renal disease are needed.
As diabetic nephropathy is characterized by extra cellular matrix accumulation, a number of studies have addressed the role of fibrinolysis regulators in this disease. Expression of PAI1 is induced in diabetic nephropathy 186 . Loss of PAI1 expression in mice reduces extracellular matrix accumulation, which is associated with increased plasmin and matrix metalloproteinase2 activity, but seems to also involve signalling via uPAR and the ERK/MAPK pathway [187] [188] [189] [190] . Notably loss or gain of PAI1 expression resulted in tubulointerstitial injury in aged nondiabetic mice, illustrating a crucial role of PAI1 in renal homeostasis in health and disease 187 . Similar to acute renal diseases (such as glomerulo nephritis, haemolytic-uraemic syndrome and other complementmediated diseases), in diabetic nephro pathy thrombomodulin suppresses complement activa tion in addition to providing a functional switch between thrombin and aPC signalling. The lectinlike domain of thrombomodulin inhibits complement activation through a poorly characterized mechanism in glucosestressed endothelial cells and podocytes and ameliorates diabetic nephropathy in mice independent of blood coagulation 191 .
Tubulointerstitial fibrosis
In diabetic patients on dialysis, levels of TAFI and acti vated TAFI are elevated, indicating impaired fibrino lysis 192 . A potential role of activated TAFI in tubular injury is supported by its induction by glucosestressed tubular cells in vitro, resulting in reduced plasmin activ ity and an increase in extracellular matrix 193 . Moreover, inhibition of TAFI reduced tubulointerstitial and glom erular fibrosis following subtotal nephrectomy in mice 194 , consistent with observations made in TAFIdeficient mice challenged with chronic glomerulo nephritis 195 . Regarding the possible involvement of PARs in tubu lointerstitial fibrosis, the increased expression of tubular PAR2 in human chronic renal disease (IgA nephropathy) and in the murine model of unilateral ureteral obstruc tion is noteworthy 196, 197 . Congruent with its profibrino genic role in other organs (such as the liver and lung), PAR2 promotes early renal tubular injury and fibrosis in the murine unilateral ureteral obstruction model 197 . Analyses of human PTCs in vitro suggest that the profi brinogenic effects of PAR2 are mechanistically linked to TGFβ and EGFR transactivation 197 . The role of coagula tion proteases in PARactivation, modulation of receptor transactivation or tubulointerstitial fibrosis in chronic renal disease models remains unresolved.
Renal transplantation
Given the roles of coagulation proteases in chronic renal diseases their impact on transplant nephropathy is of potential interest. Enhanced PAI1 expression, which seems to be reduced by rapamycin treatment, might promote chronic allograft nephropathy 198, 199 . Increased vascular expression of TF has been observed in chronic, but not in acute allograft nephropathy 200 . In addition, acute ciclosporininduced nephropathy was associated with increased TF immunoreactivity in the tubular brush border, suggesting that TF expression might be a useful diagnostic marker for this condition 200 . The rele vance of this observation remains to be established. In models of xenotransplantation, inhibition of coagula tion activation during the ischaemic period with either antithrombin or aPC markedly reduced chronic kidney graft fibrosis 201 . This observation implies that excessive coagulation activation during the ischaemic period harms the transplant and that ex vivo anticoagulation of the transplant would be beneficial without increasing the risk of haemorrhage in the recipient. Deciphering the mechanism of such longlasting effects, including the potential involvement of PARs 199 , might lead to novel clinical interventions.
Unresolved questions
Although studies evaluating the role of the haemostatic system in renal disease have provided novel patho physio logical insights, a number of questions remain. For example the kinetics of altered expression of coagulation regulators and their receptors in renal disease remain largely undefined. Whether coagulation proteases gain access to extravascular renal cell compartments through controlled mechanisms and the role of locally expressed coagulation regulators also need to be defined. Some insights into celltypespecific signalosomes have been gained, but further studies are warranted to characterize the interaction of PARs with other receptors, such as Toll like receptors and receptor tyrosine kinases (for example EGFR or VEGFR), in the context of renal diseases 28, 197 . Such insights might enable the design of kidneyspecific therapeutic approaches. Studies addressing these ques tions will likely provide new insights into the regulation of intracellular signalling pathways, tissue remodelling and sterile inflammation in renal disease. While these questions are being experimentally addressed, clini cal studies evaluating novel anticoagulants or the first clinically approved PAR antagonist (voraxapar), which might alter coagulation signalling in the kidney, should include renal end points to provide additional insight into their renal benefits and/or adverse effects. Such clini cal studies have been initiated and data might become available in the near future 105 .
Conclusions
Considerable advances have been made in understand ing the physiology and pathophysiology of coagula tion proteases, their regulators and their receptors in renal disease. Knowledge now exists of the functions of the haemostatic system conveyed via intravascular blood clotting, fibrin formation and fibrinolysis, but also through direct modulation of renal cell function through proteasedependent signalling. The identifi cation of cellspecific, PARdependent signalosomes in renal tissue has provided new pathogenic concepts and, importantly, identified potential therapeutic targets. The translation of these new insights into the clinic, however, requires further mechanistic studies. In addition, sur veillance of renal function in clinical studies evaluating new anticoagulants or therapeutics targeting PARs is required to gain insights into the function of coagula tion proteases and their receptors in humans. Based on the available data, the possibility exists, but remains to be explored, that targeting specific coagulation proteases, their receptors or underlying mechanisms might enable clinicians to improve the treatment of renal disease.
